October 21, 2019 Elevated left ventricular mass, known as left-ventricular hypertrophy, is a stronger predictor of coronary artery disease-related death and heart failure than coronary artery calcium score, according to a new study published in the journal Radiology.[1] In the study led by Nadine Kawel-Boehm, M.D., a senior staff radiologist at Hospital Graubnden in Chur, Switzerland, a team of researchers analyzed data collected in the Multi-Ethnic Study of Atherosclerosis (MESA) sponsored by the National Heart, Lung and Blood Institute. MESA is an ongoing, multi-center study of a diverse, population-based sample of 6,814 men and women age 45-84 with no known heart disease. According to Kawel-Boehm, there is little research on predicting the long-term risk of cardiovascular events in ethnically diverse patients who have magnetic resonance imaging (MRI)-identified left ventricular (LV) hypertrophy, a condition in which the muscle mass of the hearts main pumping chamber is increased Continue reading →

The National Institute for Health and Care Excellence (NICE) has published the final appraisal determination (FAD) recommending the use of Xarelto (rivaroxaban) by the National Health Service (NHS) in England at a dose of 2.5mg twice daily combined with aspirin (75100mg) once daily as an option for preventing atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are at high risk of ischaemic events.1 Publication of the NICE FAD for Xarelto (rivaroxaban) is based on evidence from the COMPASS study, the largest Phase III study with rivaroxaban (27,395 patients). This study showed that rivaroxaban vascular dose2.5mg twice daily combined with aspirin 100mg once dailystatistically significantly reduced the risk of the composite of cardiovascular (CV) death, stroke or myocardial infarction (MI) (major adverse cardiovascular events; MACE) by 24% (relative risk reduction, ARR: 1.3%) compared with aspirin 100mg once daily alone amongst patients with stable atherosclerotic vascular disease (379 patients [4.1%] vs. Continue reading →

BACKGROUND AND OBJECTIVE: Reperfusion therapy for acutemyocardial infarctionhas been shown to reduce mortality, yet it may also have deleterious effects, includingmyocardialnecrosis and no-reflow. Postconditioning is known measure for cardioprotection from reperfusion injury in animal model. Postconditioning is known measure for cardioprotection from reperfusion injury in animal model and human studies have shown inconsistent results Continue reading →

The Zion Market Research published new report on Myocardial Infarction Treatment Market by Product type (Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics); Distribution channel (Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores); and Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 2022in its database. Continue reading →